Rory J McCrimmon
Affiliation: University of Dundee
McCrimmon R, Ryan C, Frier B. Diabetes and cognitive dysfunction. Lancet. 2012;379:2291-9 pubmed publisher
..Disconcertingly, the rapid rise in obesity and type 2 diabetes in all age groups might result in a substantial increase in prevalence of diabetes-related cognitive dysfunction. ..
McCrimmon R, Henry R. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. 2018;61:2126-2133 pubmed publisher
..In addition, use of SGLT inhibitors in routine type 1 diabetes care will require specific patient and healthcare professional educational packages to ensure patient safety and to minimise risk. ..
Haythorne E, Hamilton D, Findlay J, Beall C, McCrimmon R, Ashford M. Chronic exposure to KATP channel openers results in attenuated glucose sensing in hypothalamic GT1-7 neurons. Neuropharmacology. 2016;111:212-222 pubmed publisher
McNeilly A, McCrimmon R. Impaired hypoglycaemia awareness in type 1 diabetes: lessons from the lab. Diabetologia. 2018;61:743-750 pubmed publisher
..Finally, we propose that the general process that incorporates many of these changes and results in IAH following recurrent hypoglycaemia is a form of adaptive memory called 'habituation'. ..
McNeilly A, Gallagher J, Dinkova Kostova A, Hayes J, Sharkey J, Ashford M, et al
. Nrf2-Mediated Neuroprotection Against Recurrent Hypoglycemia Is Insufficient to Prevent Cognitive Impairment in a Rodent Model of Type 1 Diabetes. Diabetes. 2016;65:3151-60 pubmed publisher
..However, in T1D, this neuroprotective mechanism is insufficient to prevent neuronal oxidative damage, resulting in chronic deficits in working and long-term memory. ..
McNeilly A, Gallagher J, Huang J, Ashford M, McCrimmon R. High-Intensity Exercise as a Dishabituating Stimulus Restores Counterregulatory Responses in Recurrently Hypoglycemic Rodents. Diabetes. 2017;66:1696-1702 pubmed publisher
..These findings may lead to novel therapeutic approaches for individuals with T1D and IAH. ..
Brown A, Lang C, MCCRIMMON R, Struthers A. Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. BMC Cardiovasc Disord. 2017;17:229 pubmed publisher
..Clinical Trials.gov: NCT02956811 . Registered November 2016. ..